Search
Filter Results
Displaying 231–240 of 756 for “retinitis clinical trial”
-
Jun 7, 2024
Eye on the Cure Podcast | Episode 67: Dr. Peter Campochiaro
Eye on the CureDr. Peter Campochiaro, a clinician-scientist and the Eccles Professor of Ophthalmology and Neuroscience at the Johns Hopkins University School of Medicine, talks to host Ben Shaberman about N-acetylcysteine (NAC), a drug that shows promise for preserving cone vision (central vision and acuity) in people with retinitis pigmentosa. The powerful antioxidant has moved into a 30+ site, Phase 3 clinical trial called NAC Attack.
-
Jun 9, 2023
The Retinal Research Community Mourns the Loss of Retinal Research Pioneer Thierry Léveillard
Beacon StoriesDr. Léveillard helped discover and develop a gene-agnostic, cone-preserving therapy for retinitis pigmentosa that’s moving into a clinical trial.
-
Aug 4, 2015
A Surprising Number of Carrier Females are Affected by X-Linked Retinitis Pigmentosa
Research News40 percent of genetically tested XLRP carriers showed a definitive abnormality in at least one of three visions tests.
-
Jan 8, 2026
RD Fund Invests in Beacon Therapeutics to Advance XLRP Gene Therapy
Research NewsThe venture philanthropy arm of the Foundation partnered with other investors to support the development of a gene therapy trial for X-linked retinitis pigmentosa (XLRP).
-
Jan 3, 2023
Opus Genetics Acquires Rights to Gene Therapies for BEST1 and RP (RHO)
Research NewsThe company plans to seek clinical trial authorization for the BEST1 gene therapy during the second half of 2023
-
May 4, 2020
#GivingTuesdayNow Featured Researcher Dr. Shannon Boye
Research NewsA Lifelong Science Nerd is Winning the Fight Against Blindness
-
Jan 19, 2017
Foundation Investing in Drug to Slow Many Forms of RP
Research NewsThe Foundation Fighting Blindness Clinical Research Institute (FFB-CRI) has announced an investment of up to $7.5 million to advance the potential therapy into and through a Phase II clinical trial.
-
Jun 24, 2016
A Steady Hand in Saving Vision
Research NewsSubretinal injection is the most common form of delivery for gene therapies currently in clinical trials.
-
May 3, 2016
ARVO 2016: What Does It Take to Develop a Stem-Cell Therapy for the Retina?
Research NewsThere are innumerable considerations for researchers developing therapies.
-
Oct 29, 2014
Low-Hanging Fruit: Repurposing Drugs to Treat Retinal Diseases
Research NewsBecause repurposing relies on prior research and clinical data, it reduces the cost and time needed to establish a new therapeutic application for the drug.